Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California. Show more

Location: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, 92130, United States | Website: https://www.connectbiopharm.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

54.45M

52 Wk Range

$0.51 - $1.60

Previous Close

$0.98

Open

$1.04

Volume

91,726

Day Range

$1.03 - $1.07

Enterprise Value

-28.61M

Cash

84.0M

Avg Qtr Burn

-8.245M

Insider Ownership

40.65%

Institutional Own.

43.97%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rademikibart (CBP-201) (Th2 cell modulator) Details Atopic dermatitis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rademikibart /CBP-201 Details Asthma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rademikibart /CBP-201 Details Acute Exacerbations in COPD	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Icanbelimod (CBP-307) (Small molecule targeting S1P1) (Th1 cell modulator) Details Ulcerative colitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CBP-174 (Peripherally restricted H3 receptor antagonist) Details Chronic pruritus	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Icanbelimod (CBP-307) (Small molecule targeting S1P1) (Th1 cell modulator) Details Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rademikibart (CBP-201) (Th2 cell modulator) Details Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.